John Park, MD
Professor
Medicine
School of Medicine

Dr. Park completed his residency training in Internal Medicine at UCLA Medical Center, and fellowship training in Hematology/Oncology at UCSF Medical Center. Dr. Park was also a visiting scientist at Genentech, Inc., where he worked on the development of trastuzumab (HerceptinTM).

Dr. Park has been the recipient of multiple honors and awards, including the ASCO Young Investigator Award, the Career Development Award from the US Department of Defense Breast Cancer Research Program, and Top Doctor from US News & World Report. Dr. Park has authored over 130 published papers and authored or edited 18 books/book chapters on cancer research. Dr. Park is also an inventor with multiple US patents relating to new cancer treatments.

Dr. Park’s major research interests include novel targeted cancer therapeutics and new cancer biomarkers. Dr. Park’s research is well known for its discovery and development of targeted therapeutics using nanoparticle/liposome/immunoliposome technologies. These include nanoliposomal irinotecan (nal-IRI, OnivydeTM), which received US FDA approval in 2015, as well as novel immunoliposome drugs. Dr. Park is also a noted expert in the field of circulating tumor cell and biomarker studies.

• Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
  NPJ breast cancer 2024 Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA
• Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
  Breast cancer research and treatment 2023 Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, …
• Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid.
  NPJ breast cancer 2021 Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS
• Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
  Journal of the National Cancer Institute 2021 Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso …
• Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
  JAMA oncology 2020 I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-…
• Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Magbanua MJM, Savenkov O, Asmus EJ, Ballman KV, Scott JH, Park JW, Dickler M, Partridge A, Carey LA, Winer EP, Rugo HS
• Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.
  Breast cancer research and treatment 2019 Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS
• Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson AL, Van't Veer LJ, Esserman L, Park JW
• Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.
  NPJ breast cancer 2018 Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW
• Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
  JCO precision oncology 2018 Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, …
• Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
  Journal of the National Cancer Institute 2018 Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-…
• Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW
• Discovery of internalizing antibodies to basal breast cancer cells.
  Protein engineering, design & selection : PEDS 2018 Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD
• Pure CTCs, advanced WGS, and precise personalized combination therapies.
  Oncoscience 2017 Peters BA, Park JW, Drmanac R
• Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer.
  Cancer research 2017 Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters …
• A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
  Cancer chemotherapy and pharmacology 2017 Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD
• Automated Microfluidic Filtration and Immunocytochemistry Detection System for Capture and Enumeration of Circulating Tumor Cells and Other Rare Cell Populations in Blood.
  Methods in molecular biology (Clifton, N.J.) 2017 Pugia M, Magbanua MJM, Park JW
• Enrichment and Detection of Circulating Tumor Cells and Other Rare Cell Populations by Microfluidic Filtration.
  Advances in experimental medicine and biology 2017 Pugia M, Magbanua MJM, Park JW
• Enumeration of Circulating Tumor Cells and Disseminated Tumor Cells in Blood and Bone Marrow by Immunomagnetic Enrichment and Flow Cytometry (IE/FC).
  Methods in molecular biology (Clifton, N.J.) 2017 Magbanua MJM, Solanki TI, Ordonez AD, Hsiao F, Park JW
• Circulating tumor cell analysis in metastatic triple-negative breast cancers.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS, Translational Breast Cancer Research Consortium
• Expression profiling of circulating tumor cells in metastatic breast cancer.
  Breast cancer research and treatment 2014 Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW
• Advances in genomic characterization of circulating tumor cells.
  Cancer metastasis reviews 2014 Magbanua MJ, Park JW
• The cancer glycocalyx mechanically primes integrin-mediated growth and survival.
  Nature 2014 Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, …
• Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors.
  Genomics data 2014 Magbanua MJ, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Melisko M, Park JW
• Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM
• Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis.
  Cancer research 2013 Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW
• A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
  British journal of cancer 2013 Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK
• Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling.
  Methods (San Diego, Calif.) 2013 Magbanua MJ, Park JW
• Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.
  Nanomedicine (London, England) 2013 Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW
• Developing safety criteria for introducing new agents into neoadjuvant trials.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P…
• Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients.
  Cancer research 2012 Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW
• Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.
  Breast cancer research and treatment 2012 Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ
• Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer.
  BMC cancer 2012 Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW
• Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012 Gedda L, Fondell A, Lundqvist H, Park JW, Edwards K
• A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
  Breast cancer research and treatment 2011 Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN
• Subtype and pathway specific responses to anticancer compounds in breast cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2011 Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, …
• Biologic markers determine both the risk and the timing of recurrence in breast cancer.
  Breast cancer research and treatment 2011 Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC
• Disseminated tumor cells: the method is the message.
  Breast cancer research and treatment 2010 Park JW
• Characterization of a novel, trastuzumab resistant human breast cancer cell line.
  Frontiers in bioscience (Elite edition) 2010 Barok M, Balazs M, Lazar V, Rakosy Z, Toth E, Treszl A, Vereb G, Colbern GT, Park JW, Szollosi J
• Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA,…
• A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW
• A comparison of RNA amplification techniques at sub-nanogram input concentration.
  BMC genomics 2009 Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM
• A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton…
• Unraveling the biologic and clinical complexities of HER2.
  Clinical breast cancer 2008 Park JW, Neve RM, Szollosi J, Benz CC
• Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.
  Nano letters 2008 Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW
• Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
  Cancer letters 2007 Barok M, Balázs M, Nagy P, Rákosy Z, Treszl A, Tóth E, Juhász I, Park JW, Isola J, Vereb G, Szöllosi J
• A role for biomarkers in the screening and diagnosis of breast cancer in younger women.
  Expert review of molecular diagnostics 2007 Esserman LJ, Shieh Y, Park JW, Ozanne EM
• Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R
• Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.
  Neuro-oncology 2007 Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS
• Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
  Molecular pharmacology 2007 Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC
• Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.
  BJU international 2007 Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ
• AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
  Magnetic resonance imaging 2007 Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM
• Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
  Neuro-oncology 2006 Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, Bankiewicz KS
• Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
  Cancer research 2006 Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW
• Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
  Neuro-oncology 2006 Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS
• Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
  Cancer research 2006 Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB
• Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.
  Cancer research 2006 Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW
• Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
  Cancer research 2005 Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW
• Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain.
  Experimental neurology 2005 Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS
• Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging.
  Brain research. Brain research protocols 2005 Krauze MT, Mcknight TR, Yamashita Y, Bringas J, Noble CO, Saito R, Geletneky K, Forsayeth J, Berger MS, Jackson P, Park JW, Bankiewicz KS
• Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS
• Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G
• Immune dysfunction and micrometastases in women with breast cancer.
  Breast cancer research and treatment 2005 Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ
• Brain metastases of breast cancer.
  Expert review of anticancer therapy 2005 Melisko ME, Kunwar S, Prados M, Berger MS, Park JW
• Future directions of liposome- and immunoliposome-based cancer therapeutics.
  Seminars in oncology 2004 Park JW, Benz CC, Martin FJ
• Development of ligand-targeted liposomes for cancer therapy.
  Expert opinion on therapeutic targets 2004 Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC
• Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.
  Cancer 2004 Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ
• Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF
• Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ
• Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.
  Journal of neuro-oncology 2004 Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS
• Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging.
  Cancer research 2004 Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS
• Liposome-based approaches to overcome anticancer drug resistance.
  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003 Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW
• Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
  Cancer research 2003 Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW